A. J. L. Leita˜o et al. / Tetrahedron Letters 49 (2008) 1694–1697
1697
Tetrahedron Lett. 2002, 43, 3801–3803; (f) Kantam, M. L.;
Jeyalakshmi, K. A. K.; Likhar, P. R. Catal. Lett. 2003, 89, 95–97;
(g) Kim, B. H.; Piao, F. Y.; Lee, E. J.; Kim, J. S.; Jun, Y. M.; Lee, B.
M. Bull. Korean Chem. Soc. 2004, 25, 881–888.
2453–2463; (d) Vanchung, V.; Tokuda, M.; Suzuki, A.; Itoh, M. Bull.
Chem. Soc. Jpn. 1976, 49, 341–342; (e) Phillipps, G. H.; Newall, C. E.;
Ayres, B. E. US Patent 3,952,031, 1976.
25. Selected analytical data: Compound 2b: Colourless liquid; IR (film)
1
15. (a) Iranpoor, N.; Tarrian, T.; Movahedi, Z. Synthesis 1996, 1473–
1476; (b) Yarapathi, R. V.; Reddy, S. M.; Tammishetti, S. React.
Funct. Polym. 2005, 64, 157–161.
16. (a) Mirkhani, V.; Tangestaninejad, S.; Yadollahi, B.; Alipanah, L.
Tetrahedron 2003, 59, 8213–8218; (b) Firouzabadi, H.; Iranpoor, N.;
Jafari, A. A.; Makarem, S. J. Mol. Catal. A: Chem. 2006, 250, 237–242.
17. Robinson, M. W. C.; Buckle, R.; Mabbett, I.; Grant, G. M.; Graham,
A. E. Tetrahedron Lett. 2007, 48, 4723–4725.
18. Guideline on the specification limits for residues of metal catalysts,
European Medicines Agency, Pre-authorisation Evaluation of Medi-
cines for Human Use; London, January 2007; Doc. Ref. CPMP/
3474, 3062, 2976, 1682, 1598, 1402, 1098 cmÀ1; H NMR (300 MHz,
CDCl3) d 1.05 (t, J = 7.0 Hz, 3H), 3.24–3.41 (m, 2H), 3.89 (s, 1H);
4.55 (d, J = 4.8 Hz, 1H), 5.33 (d, J = 4.8 Hz, 1H), 7.15–7.87 (m, 10H);
13C NMR (75 MHz, CDCl3) d 14.8, 64.7, 76.0, 83.5, 127.3, 127.9,
128.3, 128.6, 133.5, 135.1, 137.1, 199.9.
Compound 3b: Colourless liquid; IR (film) 3490, 2973, 1745, 1612,
1440, 1250, 1094 cmÀ1 1H NMR (300 MHz, CDCl3) d 1.15 (t,
;
J = 7.1 Hz, 3H), 2.48 (s, 1H), 3.29–3.51 (m, 2H), 3.78 (s, 3H), 3.80 (s,
3H), 4.23 (d, J = 3.4 Hz, 1H), 4.62 (d, J = 3.4 Hz, 1H), 6.90 (d,
J = 8.8 Hz, 2H), 7.30 (d, J = 8.8 Hz, 2H); 13C NMR (75 MHz,
CDCl3) d 15.0, 52.4, 55.2, 64.6, 75.3, 81.2, 113.7, 128.4, 129.7, 159.4,
172.6.
19. Salvador, J. A. R.; Leitao, A. J. L.; Melo, M. L. S.; Hanson, J. R.
˜
Compound 5b (anti/syn = 1/1): Colourless liquid; IR (film) 3504,
3059, 2979, 1732, 1447, 1391, 1105; 1H NMR (300 MHz, CDCl3) d
1.03 (t, J = 7.1 Hz, 3H), 1.20 (t, J = 7.0 Hz, 3H), 1.69 (s, 3H), 2.70 (s,
1H), 3.16–3.30 (m, 1H), 3.42–3.47 (m, 1H), 3.96–4.08 (m, 2H), 4.16 (s,
1H), 7.30–7.36 (m, 5H); 13C NMR (75 MHz, CDCl3) d 13.8, 13.9,
15.5, 18.7, 20.1, 58.1, 58.3, 60.9, 61.0, 78.4, 78.5, 80.4, 80.6, 126.5,
126.9, 127.4, 127.6, 128.0, 128.1, 140.9, 141.3, 171.6, 172.0.
Compound 6b: mp 179–181 °C (n-hexane/acetone); IR (film) 3477,
Tetrahedron Lett. 2005, 46, 1067–1070.
20. Despite some concern related to its toxicity, hydrazine sulphate has
been used in clinical practice for the treatment of cachexia associated
with cancer. See: Ernst, E.; Cassileth, B. R. Eur. J. Cancer 1999, 35,
1608–1613.
21. Salehi, P.; Dabiri, M.; Zolfigol, M. A.; Fard, M. A. B. Phosphorus,
Sulfur Silicon Relat. Elem. 2004, 179, 1113–1121.
22. Typical procedure: to a solution of 5b,6b-epoxy-17-oxoandrostan-3b-
yl acetate 7 (346.5 mg, 1.0 mmol) in EtOH (20 mL), NH2NH2ÁH2SO4
(13 mg, 0.1 mmol) was added. After 30 h under magnetic stirring at
50 °C the reaction was completed as verified by TLC control. The
reaction mixture was filtered, the catalyst was recovered (11 mg, 85%)
and the filtrate was concentrated under reduced pressure. The
resulting residue was purified by flash column chromatography to
afford 5a-ethoxy-6b-hydroxy-17-oxoandrostan-3b-yl acetate 7b as a
white solid (314.0 mg, 80% yield).
2939, 1735, 1026 cmÀ1 1H NMR (300 MHz, CDCl3) d 0.88 (s, 3H,
;
18-CH3), 1.14 (s, 3H, 19-CH3), 1.17 (t, J = 6.8 Hz, 3H, OCH2CH3),
2.04 (s, 3H, CH3COO), 3.08 (t, J = 2.6 Hz, 1H, 6a-H), 3.29 and 3.59
(2m, 2H, OCH2CH3), 5.14 (m, 1H, 3a-H); 13C NMR (75 MHz,
CDCl3) d 65.5 (OCH2CH3); 71.1 (C-3); 75.9 (C-5); 83.2 (C-6); 170.9
(CH3COO); 221.3 (C-17); EI-MS m/z (%): 392(14) M+, 314 (26), 270
(100), 232 (42), 179 (82), 151 (29), 91 (36), 79 (40).
Compound 7b: mp 202–204 °C (acetone); IR (film) 3523, 2941, 1731,
1023 cmÀ1; 1H NMR (300 MHz, CDCl3) d 0.88 (s, 3H, 18-CH3), 1.16
(t, J = 6.9 Hz, 3H, OCH2CH3), 1.22 (s, 3H, 19-CH3), 2.03 (s, 3H,
CH3COO), 3.29 and 3.54 (2m, 2H, OCH2CH3), 3.95 (t, J = 2.8 Hz,
1H, 6a-H), 4.86 (m, 1H, 3a-H); 13C NMR (75 MHz, CDCl3) d 55.2
(OCH2CH3); 69.9 (C-6); 71.1 (C-3); 78.5 (C-5); 170.8 (CH3COO);
221.4 (C-17); EI-MS m/z (%): 392(6) M+, 346 (8), 299 (7), 286 (90),
268 (100), 253 (26), 123 (31), 91 (41).
23. Boynton, J. A.; Hanson, J. R.; Uyanik, C. J. Chem. Res., Synop. 1995,
334–335.
24. (a) Plietker, B. Eur. J. Org. Chem. 2005, 1919–1929; (b) Hashiyama,
T.; Watanabe, A.; Inoue, H.; Konda, M.; Takeda, M.; Murata, S.;
Nagao, T. Chem. Pharm. Bull. 1985, 33, 634–641; (c) Chai, W.;
Takeda, A.; Hara, M.; Ji, S. J.; Horiuchi, C. A. Tetrahedron 2005, 61,